Digest Network Come funziona
Network
/
Società
Ne
Non verificato

Newleos Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VariePsichiatriaSalute

8 comunicati stampa

Guarda tutti i comunicati
21/10/2025
Newleos Therapeutics Appoints Timothy Noyes as President and Chief Executive Officer
Fonte
Newleos Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/10/2025
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit
Fonte
Newleos Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/09/2025
Psichiatria
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Newleos Therapeutics Announces Clinical Progress Across Neuropsychiatric Pipeline
Fonte
Newleos Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/09/2025
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Eventi
Industria
Newleos Therapeutics Announces Poster Presentation to be Featured at the 2025 World Congress of Biological Psychiatry
Fonte
Newleos Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/07/2025
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Newleos Therapeutics Appoints Stephen Brannan to Board of Directors and Announces NTX-1955 Clinical Progress in Generalized Anxiety Disorder
Fonte
Newleos Therapeutics, Inc.
Emittente
Business Wire
1.00
0
29/04/2025
Mercato del lavoro
Industria
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Newleos Therapeutics Announces Clinical Advisory Board to Support Key Neuropsychiatry Programs
Fonte
Newleos Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/04/2025
Mercato del lavoro
Biotecnologia
Psichiatria
Salute
Farmaceutica
Medicina - Varie
Newleos Therapeutics Expands Leadership Team to Advance its Clinical-Stage Neuropsychiatric Programs and Drive Corporate Growth
Fonte
Newleos Therapeutics, Inc.
Emittente
Business Wire
1.00
0
13/02/2025
Finanza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Associazioni/Professionisti
Medicina - Varie
Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines
Fonte
Newleos Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0